Nivolumab/Ipilimumab Showcases Prolonged Treatment-Free Survival in Advanced RCC
OncLive,
Over a 42-month period, the combination of nivolumab and ipilimumab induced a longer treatment-free survival compared with…
Over a 42-month period, the combination of nivolumab and ipilimumab induced a longer treatment-free survival compared with…
A longer treatment-free survival was seen in patients with advanced renal cell carcinoma who were treated with first-line…
(HealthDay News) — For patients with advanced renal cell carcinoma (aRCC), those initiating treatment with nivolumab plus…
HealthDay News — For patients with advanced renal cell carcinoma (aRCC), those initiating treatment with nivolumab plus…